The association between APOL1 risk alleles and longitudinal kidney function differs by HIV viral suppression status

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 646-652

  Estrella, Michelle M ^a   Li, Man ^b   Tin, Adrienne ^b   Abraham, Alison G ^b   Shlipak, Michael G ^c,d,e   Penugonda, Sudhir ^f   Hussain, Shehnaz K ^g,h   Palella, Frank J ^f   Wolinsky, Steven M ^f   Martinson, Jeremy J ⁱ   Parekh, Rulan S ^a,b,j   Kao, W H Linda ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of Medicine ^*  (United States)

^d University of California   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

antiretroviral therapy; genetic; HIV; kidney disease

Indexed keywords

APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; VIRUS RNA;

AFRICAN AMERICAN; ALLELE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VIROLOGY; VIRUS LOAD;

AFRICAN AMERICANS; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOLIPOPROTEINS; COHORT STUDIES; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLOMERULAR FILTRATION RATE; HIV; HIV INFECTIONS; HUMANS; KIDNEY; LIPOPROTEINS, HDL; MALE; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 84922355262     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu765     Document Type: Article

References (26)

1. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ endstage renal disease. J Am Soc Nephrol 2005; 16:2412-20
2. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-Associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-6
3. Althoff KN, Abraham AG, Estrella MM, et al. Incidence of End-Stage Renal Disease in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). In: International AIDS Society, Kuala Lumpur, Malaysia, 2013
4. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-5
5. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-Associated nephropathy. J Am Soc Nephrol 2011; 22:2129-37
6. Estrella MM, Wyatt CM, Pearce CL, et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013; 84:834-40
7. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-8
8. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3 (suppl ):1-150
10. Kosoy R, Nassir R, Tian C, et al. Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat 2009; 30:69-78
11. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155:945-59
12. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269:729-30
13. Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, 2009:1-161. Available at: http://aidsinfo.nih.gov//guidelines. Accessed 3 November 2008
14. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33:278-85
15. Papeta N, Chan KT, Prakash S, et al. Susceptibility loci for murine HIVassociated nephropathy encode trans-regulators of podocyte gene expression. J Clin Invest 2009; 119:1178-88
16. Fine DM, Wasser WG, Estrella MM, et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 2012; 23:343-50
17. Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013; 24:1484-91
18. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369:2183-96
19. Ganesan A, Krantz EM, Huppler Hullsiek K, et al. Determinants of incident chronic kidney disease and progression in a cohort of HIVinfected persons with unrestricted access to health care. HIV Med 2013; 14:65-76
20. Taylor HE, Khatua AK, Popik W. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol 2014; 88:592-603
21. Bruggeman LA, O'Toole JF, Ross MD, et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 2014; 25:634-44
22. Reeves-Daniel AM, DePalma JA, Bleyer AJ, et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11:1025-30
23. Lee BT, Kumar V, Williams TA, et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12:1924-8
24. Ma L, Shelness GS, Snipes JA, et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 2014; doi:10.1681/ASN.2013091017
25. Ulasi II, Tzur S, Wasser WG, et al. High population frequencies of APOL1 risk variants are associated with increased prevalence of nondiabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013; 123:123-8
26. Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol 2011; 7:313-26